During the last three months, 18 analysts shared their evaluations of Regeneron Pharmaceuticals REGN, revealing diverse outlooks from bullish to bearish. The table below offers a condensed view of ...

Following a sell-side Q&A session with Regeneron's management, the analysts received confirmation of the company's strategic emphasis on advancing its pipeline. Management's intention to shift the ...